Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.42 |
| ▸ | CDK2 | P24941 | 3/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND3 | P30281 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792298 | 0.89 | CCNA2 (0.43) | SMN1; SMN2CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL6786625 | 0.89 | CCNA2 (0.41) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL6794887 | 0.86 | CCNA2 (0.41) | SMN1; SMN2CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL6791026 | 0.84 | SMN1; SMN2 (0.42) | SMN1; SMN2CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL6794542 | 0.82 | CCNA2 (0.40) | CCNA2CDK2CCNA1CDK4CCND3 | |
| SCHEMBL6792515 | 0.76 | SMN1; SMN2 (0.39) | SMN1; SMN2CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL6798193 | 0.76 | ALDH1A1 (0.41) | SMN1; SMN2CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL6791828 | 0.76 | CDK2 (0.45) | CCNA2CDK2CCNA1POLB | |
| SCHEMBL6792545 | 0.75 | CDK4 (0.36) | SMN1; SMN2CCNA2CDK2CCNA1CDK4 | |
| SCHEMBL6793803 | 0.74 | AURKA (0.51) | SMN1; SMN2CCNA2CDK2CCNA1CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | PHARMACIA CORPORATION | 2004-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127492-A1 | Cyclic pyrazoles for the inhibition of mitogen activated protein kinase-activated protein kinase-2 | MKNK2, MAPKAPK2, MAP3K2 | SMN1; SMN2 4333/4885CCNA2 270/4885CDK2 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.